Merck KGaA to buy biotech SpringWorks for $3.9B
The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.
The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.
